AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: Single dose by subcutaneous injection
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varivax
Description: Single dose by subcutaneous injection
Study NCT00345683 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: Single dose by subcutaneous injection
Study NCT01893866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 x 30 mg/mL pegvisomant
Description: Subcutaneous injection, 30 mg, single dose.
Study NCT01893866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 x 15 mg/mL pegvisomant
Description: Subcutaneous injection, 2 injections of 15 mg, single dose.
Study NCT03805178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Initial phase: 10 mg/kg on days 0 and 4, and again at weeks 2 and 4. Maintenance phase: 10 mg/kg every month beginning 4 weeks after completion of the initial phase.~No dosage adjustments required for renal or hepatic impairment. No known drug interactions for usual post-transplant medication regimen.
Study NCT03805178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: 20mg/m2 Plasmapheresis
Study NCT03256513 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: model controlling
Description: control blood pressure by statistical l model with anticipate lowest peri-procedure risk
Study NCT03256513 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional controlling
Description: control blood pressure by conventional strategy
Study NCT01796431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eviplera®
Study NCT02893852 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard CO-OP Approach
Description: The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems and to support generalization and transfer of skills.
Study NCT02893852 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: standard CO-OP Approach plus coaching parents
Description: CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
Study NCT03560505 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound protocol
Description: High-resolution ultrasound protocol at pre-defined sites bilaterally. Pre-defined sites: Sciatic nerve (proximal and distal), tibial nerve (proximal and distal), common fibular nerve (proximal and distal), superficial fibular nerve (proximal and distal) and sural nerve (proximal and distal).
Study NCT01268449 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Low dose laser
Description: 5mv laser with a wavelength of 650nm
Study NCT01268449 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The act of radiating laser to the ear is done while the set is off.
Study NCT03678961 — intervention group
Intervention type: BEHAVIORAL
Intervention: external rotation of leg
Description: external rotation of leg by 45 degrees
Study NCT03678961 — intervention group
Intervention type: BEHAVIORAL
Intervention: hip flexion and knee flexion
Description: hip flexion by 15/45 degrees and knee flexion by 15/45 degrees
Study NCT03074279 — intervention group
Intervention type: OTHER
Intervention: Interview with a psychologist and self-reported questionnaires
Description: The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
Study NCT01196481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol+VSL#3
Description: Tablet Carvedilol 6.25 mg BD \& capsule VSL#3 1 TDS for 2 year
Study NCT01196481 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol+VSL#3
Description: Tablet Carvedilol 6.25 mg BD \& capsule VSL#3 1 TDS for 2 year
Study NCT01196481 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic variceal ligation
Description: In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
Study NCT04022070 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Dynamic Tape® (Tape)
Description: To evaluate the evolution of this symptomatology prior to and thereafter the application of Dynamic Tape® bandage affected by plantar fasciitis during a week the Outcome Measure, pain is evaluate with a VAS (visual pain scale).
Study NCT00894985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: heparin sodium - blausiegel
Description: heparin sodium 5.000UI
Study NCT00894985 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: heparin sodium - APP
Description: heparin sodium 5.000 USP - APP
Study NCT01132287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FID 112903
Description: lubricant eye drop FID 112903
Study NCT01951183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: RO681135 placebo subcutaneously daily
Study NCT01951183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6811135
Description: Subcutaneously daily
Study NCT06334926 — intervention group
Intervention type: OTHER
Intervention: no intervention, retrospective data analysis
Description: not applicable, retrospective data analysis
Study NCT04076306 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: iSTEP exercise testing
Description: iSTEP 10 minute step test, up and down on a commercial standard 3-height adjustable step Undertaking the 10m-MSWT 20-30 minutes Procedure takes place on testing track at Great Ormond Street Hospital; a 5 minute walk from the Haemophilia Centre. One of the research team accompanies the family with child to the track and will accompany them back to the Centre once testing is finished. Muscle Myometry 10 minutes, carried out by one of the research team at the end of the physiotherapy clinical assessment in the Haemophilia Centre. Wearing of accelerometer (activity/ step counter)7 days Device will be set up and provided at the end of the testing on the day of attendance at clinic. They will be instructed to wear this throughout the week at home when they are awake (at least 8 hours). Haemophilia Joint Health Score (HJHS) - a standardised outcome measure of joint health in people with Haemophilia, undertaken by the Clinical Specialist Physiotherapists in Haemophilia.
Study NCT02707432 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Heart Matters
Description: Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages.
Study NCT04887545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics analysis of pleural effusion
Description: Pleural effusion removed as part of standard care is fractionized and analyzed by mass spectrometry
Study NCT02019979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
Study NCT02019979 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: carbohydrate restricted diet
Description: addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
Study NCT02061085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulina
Study NCT01681771 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy
Description: Internet based, weekly home task and weekly feedback provided by health care professional.
Study NCT01681771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behaviour therapy
Description: Internet based, weekly home task and weekly feedback provided by health care professional.
Study NCT01681771 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion group
Description: Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
Study NCT03615456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional thyroidectomy
Description: Thyroid vessels are ligated with sutures and divided
Study NCT03615456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Harmonic scalpel thyroidectomy
Description: Thyroid vessels are sealed using harmonic scalpel device
Study NCT02757300 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypopharyngeal packing
Description: After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
Study NCT02757300 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Without Hypopharyngeal packing
Description: After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
Study NCT02996435 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application Intervention
Description: Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
Study NCT02996435 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Participants will receive physician- or nurse-guided standard of care.
Study NCT01400672 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Lysate Vaccine
Description: Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
Study NCT01400672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
Study NCT01400672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy.
Study NCT04193722 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy
Description: Hyperbaric oxygen therapy in a multiperson hyperbaric oxygen chamber. Standard hyperbaric oxygen therapy provided as reimbursed by insurers.
Study NCT01577095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EA + Rosiglitazone
Description: electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
Study NCT01577095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TZD
Description: Rosiglitazone 8 mg single dose
Study NCT02827513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN SR1
Study NCT02827513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN XR1
Study NCT02827513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN XR2
Study NCT02827513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTN XR3
Study NCT03821324 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Venus Viva
Description: The Venus Viva™ fractional RF device has been shown in clinical studies to improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids and scars. Beginning with the Baseline visit (Visit 1), subjects will receive a total of 3 treatments approximately 3-5 weeks apart. The left and right side of the face will be treated and assessed as independent sites, and the same applicator tip configuration will be used to treat both sides at all 3 treatment visits.
Study NCT02314533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fenofibrate
Description: Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
Study NCT03335943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDA-2 (Cell Differentiation Agent 2)
Description: CDA-2 will be given intravenously, with 200 ml each day for 14 consecutive days in every four weeks (one cycle). The treatment will be repeated at least for 3 cycles.
Study NCT01700920 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspirate
Study NCT04091269 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence
Description: The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
Study NCT04091269 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence
Description: The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
Study NCT04091269 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: automatic adjustmen of inspiratory triger and cycling-off based on waveform and PSV with fixed Esence
Description: The ventilators have a compunter drived funcation of automatic adjustmen of inspiratory triger and cycling-off based on waveform, IntelliCycleTM 2.0.
Study NCT03163095 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open Abdomen Management with ANPPT dressing
Description: The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.~The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.~Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment.
Study NCT03163095 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Closed Abdomen Management
Description: Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).~This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.~Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment.
Study NCT02962882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Border
Description: Multi-layer Foam Dressings
Study NCT02625415 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin B6 cream
Description: Topical Vitamin B6 cream
Study NCT02625415 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vitamin B6 cream
Description: Placebo Vitamin B6 cream
Study NCT00991250 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SentoClone®
Description: SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
Study NCT00991250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temodal® or Dacarbazine Medac®
Description: Dacarbazine (5-\[3,3-Dimethyl-1-triazenyl\]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.~A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver.
Study NCT04001465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volumetric methacholine challenge unmodified
Description: Bronchoprovocation challenge performed per volumetric method
Study NCT04001465 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified volumetric methacholine challenge
Description: Bronchoprovocation challenge performed per volumetric method modified to include use of ultrasonic spirometer fitted with vibrating mesh nebulizer
Study NCT03101423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interleukin-2
Description: On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
Study NCT03101423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donor Regulatory T-Lymphocytes
Description: On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
Study NCT00360867 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMG 706
Description: The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
Study NCT04733352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: to conduct acupuncture on different acupoints
Study NCT02945280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apixaban
Description: 12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
Study NCT00582101 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based HIV Prevention for Latinos
Description: 7-hour one-day workshop with adolescents and parents in separate and joint sessions
Study NCT00582101 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 7 hour one-day workshop on general health promotion topics
Study NCT01965756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study NCT01965756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Study NCT02962583 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Weight loss
Study NCT02962583 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight loss
Study NCT02962583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Study NCT02962583 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT04090229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASLAN004
Description: Subcutaneous injections of ASLAN004 100 mg/mL will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.
Study NCT04090229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASLAN004 Placebo
Description: Subcutaneous injections of ASLAN004 Placebo will be administered into the thigh or abdomen, except for the 2 inches (5 cm) around the navel.